CN101027284B - （3-氰基-1h-吲哚-7-基）-[4-（4-氟苯乙基）-哌嗪-1-基]-甲酮盐酸盐的晶体形式 - Google Patents

（3-氰基-1h-吲哚-7-基）-[4-（4-氟苯乙基）-哌嗪-1-基]-甲酮盐酸盐的晶体形式 Download PDF

Info

Publication number
CN101027284B
CN101027284B CN2005800326518A CN200580032651A CN101027284B CN 101027284 B CN101027284 B CN 101027284B CN 2005800326518 A CN2005800326518 A CN 2005800326518A CN 200580032651 A CN200580032651 A CN 200580032651A CN 101027284 B CN101027284 B CN 101027284B
Authority
CN
China
Prior art keywords
crystalline form
indol
cyano
fluorophenethyl
emd281014
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800326518A
Other languages
English (en)
Chinese (zh)
Other versions
CN101027284A (zh
Inventor
A·巴特
B·黑尔弗特
R·克尼里梅
C·扎尔
R·凯纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN101027284A publication Critical patent/CN101027284A/zh
Application granted granted Critical
Publication of CN101027284B publication Critical patent/CN101027284B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
CN2005800326518A 2004-09-28 2005-09-08 （3-氰基-1h-吲哚-7-基）-[4-（4-氟苯乙基）-哌嗪-1-基]-甲酮盐酸盐的晶体形式 Expired - Fee Related CN101027284B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004047517A DE102004047517A1 (de) 2004-09-28 2004-09-28 Neuartige Kristallform von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, Hydrochlorid
DE102004047517.2 2004-09-28
PCT/EP2005/009647 WO2006034774A1 (de) 2004-09-28 2005-09-08 Neuartige kristallform von (3-cyan-1h-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, hydrochlorid

Publications (2)

Publication Number Publication Date
CN101027284A CN101027284A (zh) 2007-08-29
CN101027284B true CN101027284B (zh) 2010-09-29

Family

ID=35285234

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800326518A Expired - Fee Related CN101027284B (zh) 2004-09-28 2005-09-08 （3-氰基-1h-吲哚-7-基）-[4-（4-氟苯乙基）-哌嗪-1-基]-甲酮盐酸盐的晶体形式

Country Status (16)

Country Link
US (1) US7981897B2 (enExample)
EP (1) EP1794121B1 (enExample)
JP (1) JP5160892B2 (enExample)
KR (1) KR20070057872A (enExample)
CN (1) CN101027284B (enExample)
AR (1) AR051043A1 (enExample)
AU (1) AU2005289169B2 (enExample)
BR (1) BRPI0516200A (enExample)
CA (1) CA2581834A1 (enExample)
DE (1) DE102004047517A1 (enExample)
MX (1) MX2007003471A (enExample)
PE (1) PE20060964A1 (enExample)
RU (1) RU2383532C2 (enExample)
TW (1) TW200616952A (enExample)
WO (1) WO2006034774A1 (enExample)
ZA (1) ZA200703440B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101437793B (zh) * 2006-05-05 2012-08-22 默克专利股份有限公司 结晶的（3-氰基-1h-吲哚-7-基）-[4-（4-氟苯乙基）哌嗪-1-基]甲酮磷酸盐
KR20090017569A (ko) * 2006-05-05 2009-02-18 메르크 파텐트 게엠베하 결정질 (３-시아노-１ｈ-인돌-７-일)-[４-(４-플루오로펜에틸)피페라진-１-일]메탄온 포스페이트
HUE033357T2 (en) * 2007-05-11 2017-11-28 Richter Gedeon Nyrt Crystalline form of carbamoylcyclohexane derivatives
HUP0700353A2 (en) * 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US7875610B2 (en) * 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
WO2009104739A1 (ja) * 2008-02-21 2009-08-27 田辺三菱製薬株式会社 経口投与用固形製剤
UA104869C2 (uk) 2008-07-16 2014-03-25 Ріхтер Гедеон Нірт. Фармацевтичні композиції, що містять ліганди рецептора дофаміну
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
WO2014031162A1 (en) 2012-08-20 2014-02-27 Forest Laboratories Holdings Limited Crystalline form of carbamoyl-cyclohexane derivatives
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1364157A (zh) * 1999-07-22 2002-08-14 默克专利股份公司 N－(吲哚羰基)哌嗪衍生物
CN1487923A (zh) * 2001-01-23 2004-04-07 Ĭ��ר���ɷ����޹�˾ (3-氰基-1h-吲哚-7-基)(4-(4-氟苯乙基)哌嗪-1-基)-甲酮及其盐的制备方法
WO2004032932A1 (de) * 2002-10-04 2004-04-22 Merck Patent Gmbh Verwendung von 5-ht2-rezeptorantagonisten zur behandlung von schlafstörungen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2084531A1 (en) * 1991-12-19 1993-06-20 David W. Smith Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
DE10157673A1 (de) 2001-11-24 2003-06-05 Merck Patent Gmbh Verwendung von N-(Indolcarbonyl-)piperazinderivaten

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1364157A (zh) * 1999-07-22 2002-08-14 默克专利股份公司 N－(吲哚羰基)哌嗪衍生物
CN1487923A (zh) * 2001-01-23 2004-04-07 Ĭ��ר���ɷ����޹�˾ (3-氰基-1h-吲哚-7-基)(4-(4-氟苯乙基)哌嗪-1-基)-甲酮及其盐的制备方法
WO2004032932A1 (de) * 2002-10-04 2004-04-22 Merck Patent Gmbh Verwendung von 5-ht2-rezeptorantagonisten zur behandlung von schlafstörungen

Also Published As

Publication number Publication date
ZA200703440B (en) 2008-08-27
RU2383532C2 (ru) 2010-03-10
BRPI0516200A (pt) 2008-08-26
CN101027284A (zh) 2007-08-29
US7981897B2 (en) 2011-07-19
EP1794121B1 (de) 2013-12-25
EP1794121A1 (de) 2007-06-13
AU2005289169B2 (en) 2011-07-14
MX2007003471A (es) 2007-05-10
TW200616952A (en) 2006-06-01
JP5160892B2 (ja) 2013-03-13
KR20070057872A (ko) 2007-06-07
AU2005289169A1 (en) 2006-04-06
JP2008514558A (ja) 2008-05-08
RU2007116037A (ru) 2008-11-10
DE102004047517A1 (de) 2006-03-30
AR051043A1 (es) 2006-12-13
CA2581834A1 (en) 2006-04-06
US20070259885A1 (en) 2007-11-08
WO2006034774A1 (de) 2006-04-06
PE20060964A1 (es) 2006-10-02

Similar Documents

Publication Publication Date Title
JP5714824B2 (ja) １−４−（５−シアノインドール−３−イル）ブチル−４−（２−カルバモイルベンゾフラン−５−イル）ピペラジン塩酸塩の多形相
CN101027284B (zh) （3-氰基-1h-吲哚-7-基）-[4-（4-氟苯乙基）-哌嗪-1-基]-甲酮盐酸盐的晶体形式
CN104797566A (zh) 沃替西汀氢溴酸盐的新结晶形式
KR20150036336A (ko) 타이로신 키나제 억제제 다이말리에이트의 결정형 아이 및 그의 제조 방법
JP2005529103A (ja) 新規多形及び偽多形
KR102402501B1 (ko) 피마살탄 트로메타민염 및 이를 포함하는 약제학적 조성물
WO2016169422A1 (zh) 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
WO2017160703A1 (en) Solid state forms of nilotinib salts
CN104496994B (zh) 一种炔类杂芳基化合物的新晶型
JP6761564B2 (ja) ナトリウム・グルコース共輸送体２阻害薬のｌ−プロリン化合物、およびｌ−プロリン化合物の一水和物および結晶
HK1105413A (en) Novel crystalline form of (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)-piperazine-1-yl]-methanon hydrochloride
JP6823359B2 (ja) インドール誘導体の塩及びその結晶
KR20200134928A (ko) 발사르탄/사쿠비트릴 3소듐염 수화물의 결정형 및 그 제조방법
JP2019514862A (ja) （ｓ）−２−（ジフェニルアセチル）−１，２，３，４−テトラヒドロ−６−メトキシ−５−（フェニルメトキシ）−３−イソキノリンカルボン酸ナトリウムの無水結晶形
ZA200302520B (en) Crystal forms of 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl] piperazine.hydrochloride.
EP2860184A1 (en) Dihydrogenphosphate salt of Tenofovir disoproxil
TWI754605B (zh) 吲哚衍生物之鹽及其結晶
KR20080106232A (ko) 베시피르딘 클로하이드레이트의 결정형, 그 제조 방법 및 용도
WO2021208055A1 (zh) 一种噻吩并哒嗪类化合物的晶型及其制备方法和应用
JP2007510640A (ja) 選択的セロトニン再取込み阻害剤の多形体の製造方法
HK1248213A1 (zh) Abexinostat 甲苯磺酸盐及相关的晶体形式的制备方法
JPH10503532A (ja) レソピトロン二塩酸塩の新規多形およびその水和形その製造方法およびそれを含有する組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1105413

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1105413

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100929

Termination date: 20140908

EXPY Termination of patent right or utility model